Why the United States medical marijuana industry has been so successful has been partly down to the fact that it was created by the people who want to help people suffering from diseases that have no cure.
“The people who create the product are very knowledgeable about it and very knowledgeable in their own right,” said John W. Campbell, a professor of psychiatry at the University of Washington.
“And they are really good at marketing.”
In this case, the people behind medical marijuana have been able to harness the unique properties of marijuana to treat a specific type of pain that is extremely rare in the world.
The drug is known as cannabidiol, or CBD.
The plant is derived from the leaves of the cannabis plant, but it also contains another substance called cannabigerol, which is a chemical found in marijuana.CBD has been shown to help alleviate symptoms of multiple sclerosis, epilepsy, multiple sclerosis and cancer.
It has also been shown in animal studies to help treat epilepsy and to help with nausea and vomiting, as well as pain.
CBD is believed to be a compound that was first synthesized in the early 1800s and then refined and distilled into its present form, which was created in the 1970s and was discovered by a pharmaceutical company in Israel.
For decades, the FDA has approved cannabimimetic products, including CBD and THC-rich products, as a means of treating certain medical conditions.
But now, with the approval of CBD-based medical products in recent years, the agency has taken a more proactive approach to cannabis-based medicine.
In 2016, the DEA approved the medical use of CBD for treating the symptoms of Crohn’s disease, a disease that affects about 6.5 million Americans and causes the body to produce more than 400,000 inflammatory and autoimmune reactions, according to the American Medical Association.
“It’s a tremendous step forward,” said Campbell.
“There’s nothing else in the medical world as effective as CBD and it’s not only beneficial for the people with Crohn, it’s good for the doctors who prescribe it.”
Cannabidiodiol is the first non-psychoactive cannabinoid to be approved by the FDA.
Its ability to ease pain, nausea and other symptoms associated with Crohns is the reason why the American Academy of Pain Medicine has endorsed the use of it in the treatment of Crohn’s.
The U.S. Department of Veterans Affairs approved the use and distribution of cannabigital products in May of this year.
While the FDA’s move to approve medical marijuana for use in treating Crohn disease has been hailed by medical marijuana advocates, some experts say that the drug will likely be too difficult to make and that there is a significant risk that it will cause problems with the supply chain.
Even though CBD is the most widely used psychoactive cannabinoid, the U.K.-based medical marijuana company, Green Mountain, is not the first company to try it.
Green Mountain began as a lab, which manufactured CBD-rich cannabis extract, and since then has developed a proprietary extraction process.
That process produces CBD-infused cannabis that has a high level of THC, the psychoactive chemical found inside the plant.
However, the company is not selling any of the product to the general public, nor is it available in a generic form.
This lack of access has been problematic, according an industry source.
One source said the FDA had been slow to approve products that were less expensive to produce and to distribute.
A company source told CBS News that the FDA is also taking a more cautious approach to CBD-derived medical products, and that the agency’s decision to allow the plant to be used in pain management products is not a good sign.
With CBD being so highly sought after and expensive, Green-Mountain may struggle to secure the supply that would be required to manufacture it.